<code id='4457475E43'></code><style id='4457475E43'></style>
    • <acronym id='4457475E43'></acronym>
      <center id='4457475E43'><center id='4457475E43'><tfoot id='4457475E43'></tfoot></center><abbr id='4457475E43'><dir id='4457475E43'><tfoot id='4457475E43'></tfoot><noframes id='4457475E43'>

    • <optgroup id='4457475E43'><strike id='4457475E43'><sup id='4457475E43'></sup></strike><code id='4457475E43'></code></optgroup>
        1. <b id='4457475E43'><label id='4457475E43'><select id='4457475E43'><dt id='4457475E43'><span id='4457475E43'></span></dt></select></label></b><u id='4457475E43'></u>
          <i id='4457475E43'><strike id='4457475E43'><tt id='4457475E43'><pre id='4457475E43'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:focus    Page View:8565
          Adam's take main illustration
          Molly Ferguson/STAT

          This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

          The next ALS data readout — overdue but important

          A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

          advertisement

          In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In